港股異動丨同仁堂科技大漲近8% 旗下眾多藥品為抗擊疫情所需的一線用藥
格隆匯2月6日丨同仁堂科技(1666.HK)大漲近8%,報8.14港元,成交3818萬港元,總市值104.26億港元。

據悉,從1月22日至1月30日,同仁堂科技發展集團物流配送中心已經發出3.3萬件防控疫情所需藥品。同仁堂科技發展集團物流配送中心近日訂單涉及十餘個藥品品種,大部分為藿香正氣水、感冒清熱顆粒、防風通聖等抗擊疫情所需的一線用藥。這些藥品收貨人遍佈全國的80餘家經銷商和零售終端。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.